Search
Cilostazol
go.drugbank.com/drugs/DB01166ApprovedInvestigationalIt is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.
MPI-674
go.drugbank.com/drugs/DB05749ExperimentalAIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen.
Cambinol
go.drugbank.com/drugs/DB15493ExperimentalThis activity is currently being investigated for its use as a cancer treatment.
Tasimelteon
go.drugbank.com/drugs/DB09071ApprovedInvestigationalBy activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism … Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Imidafenacin
go.drugbank.com/drugs/DB09262InvestigationalIt is marketed in Japan under the tradenames Staybla by Ono Pharmaceutical and Uritos by Kyojin Pharmaceutical.
3,4-Methylenedioxy-N-isopropylamphetamine
go.drugbank.com/drugs/DB06112ExperimentalMDI-P has demonstrated potent anti-HIV activity. MDI-P has been shown to be effective in killing HIV in cell culture. HIV is the virus that causes acquired immune deficiency syndrome (AIDS). MDI-P is also a potential therapeutic agent fo...
KC706
go.drugbank.com/drugs/DB05157InvestigationalKC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase.
Propyl alcohol
go.drugbank.com/drugs/DB03175ApprovedA colorless liquid made by oxidation of aliphatic hydrocarbons that is used as a solvent and chemical intermediate.
IR208
go.drugbank.com/drugs/DB05106InvestigationalIR208 is a synthetic T-Cell receptor peptide vaccine developed by Immune Response Corporation. … It contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II studies in a 200-patient trial.